Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29011426 | 0.81 | TSHR (0.45) | TSHRALDH1A1THRB | |
| SCHEMBL30199376 | 0.78 | TSHR (0.45) | TSHRALDH1A1THRB | |
| SCHEMBL14647911 | 0.78 | TSHR (0.39) | TSHRALDH1A1THRB | |
| SCHEMBL94906 | 0.78 | TSHR (0.68) | TSHRALDH1A1THRB | |
| SCHEMBL331867 | 0.77 | TSHR (0.38) | TSHRTHRB | |
| SCHEMBL30170509 | 0.76 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL19998240 | 0.76 | TSHR (0.65) | TSHRALDH1A1THRB | |
| SCHEMBL5675768 | 0.73 | ALDH1A1 (0.37) | TSHRALDH1A1 | |
| SCHEMBL1943351 | 0.73 | TSHR (0.57) | TSHRALDH1A1THRB | |
| SCHEMBL3078233 | 0.73 | TSHR (0.57) | TSHRALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053489-B2 | Crosslink agents and dual radical cure polymer | BAUSCH & LOMB INCORPORATED (US) | 2011-11-08 | — | — | US | claimed |
| US-12565554-B2 | Dual-phase zwitterionic monomers | KUNZLER BIOMEDICAL LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250326873-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | Envision Biomedical LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12371519-B2 | Dual-phase zwitterionic monomers | Envision Biomedical LLC (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250092174-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | Envision Biomedical LLC (US) | 2025-03-20 | — | — | US | disclosed |
| US-11905351-B2 | Silicone hydrogel materials | Envision Biomedical LLC (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240026049-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | Envision Biomedical LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-8252850-B2 | Crosslink agents | BAUSCH & LOMB INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-8119753-B2 | Silicone hydrogels with amino surface groups | BAUSCH & LOMB INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-8053489-B2 | Crosslink agents and dual radical cure polymer | BAUSCH & LOMB INCORPORATED (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110105779-A1 | CROSSLINK AGENTS | ORAPHARMA, INC. | 2011-05-05 | — | — | US | disclosed |
| EP-2170966-B1 | CROSSLINK AGENTS AND DUAL RADICAL CURE POLYMER | BAUSCH & LOMB (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7901073-B2 | Silicone hydrogel with composite hydrophilic and silicone polymers prepared with selective crosslink agents | BAUSCH & LOMB INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7781554-B2 | Polysiloxanes and polysiloxane prepolymers with vinyl or epoxy functionality | BAUSCH & LOMB INCORPORATED (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090227804-A1 | POLYSILOXANES AND POLYSILOXANE PREPOLYMERS WITH VINYL OR EPOXY FUNCTIONALITY | PRECISION DERMATOLOGY, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090103045-A1 | SILICONE HYDROGELS WITH AMINO SURFACE GROUPS | SALIX PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090023876-A1 | Crosslink Agents and Dual Radical Cure Polymer | MEDICIS PHARMACEUTICAL CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090018233-A1 | Crosslink Agents and Dual Radical Cure Polymer | SOLTA MEDICAL, INC. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105779-A1 | CROSSLINK AGENTS | UACA, CRYAA, DCLRE1A | TSHR 3185/4885ALDH1A1 2278/4885THRB 4732/4885 |
| US-20250092174-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | RAD1, RAD51, VCL | TSHR 3440/4885ALDH1A1 600/4885THRB 3157/4885 |
| US-20090018233-A1 | Crosslink Agents and Dual Radical Cure Polymer | UACA, CRYAA, RAD51 | TSHR 2555/4885ALDH1A1 1327/4885THRB 4577/4885 |
| US-20090227804-A1 | POLYSILOXANES AND POLYSILOXANE PREPOLYMERS WITH VINYL OR EPOXY FUNCTIONALITY | MUS81, UTS2R, C1R | TSHR 2214/4885ALDH1A1 2339/4885THRB 3182/4885 |
| US-12565554-B2 | Dual-phase zwitterionic monomers | HAO2, CRYZ, CRYAA | TSHR 1764/4885ALDH1A1 851/4885THRB 1186/4885 |
| US-20250326873-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | RAD1, RAD51, VCL | TSHR 3440/4885ALDH1A1 600/4885THRB 3157/4885 |
| US-20090023876-A1 | Crosslink Agents and Dual Radical Cure Polymer | UACA, CRYAA, PCNA | TSHR 2788/4885ALDH1A1 883/4885THRB 4718/4885 |
| US-20240026049-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | RAD1, RAD51, VCL | TSHR 3440/4885ALDH1A1 600/4885THRB 3157/4885 |
| US-12371519-B2 | Dual-phase zwitterionic monomers | RAD1, RAD51, VCL | TSHR 3440/4885ALDH1A1 600/4885THRB 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.